Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Qingsheng Li · UNIVERSITY OF NEBRASKA LINCOLN · 2024 · $650,156 — Summary Novel vaccine strategies is needed to develop a safe, effective, and broadly accessible HIV vaccine to end the HIV pandemic. This proposal is built upon several innovative advancements. First, learned from natural immunity observed in a group of HIV resistant Kenyan female sex workers, we fo…
MICHAEL N STARNBACH · HARVARD MEDICAL SCHOOL · 2024 · $205,449 — Chlamydia trachomatis is an obligate intracellular bacterium and the most prevalent sexually transmitted infection in the United States. If untreated, infection can lead to pelvic inflammatory disease, ectopic pregnancy, and infertility. Although C. trachomatis infection is treatable with antibiotic…
Nicolas Wentzensen · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · 2024 · $535,504 — The following research projects are etiologic and human population based and all have various molecular components: SUCCEED directed by Dr. Wentzensen is a cross-sectional study among women referred for abnormal cevrical cancer screening results focused on the identification of biomarkers of risk at…
Lisa Jenkins · DIVISION OF BASIC SCIENCES - NCI · 2024 · $1,295,034 — Overall, the expertise of the Mass Spectrometry Resource is being used to further the research of multiple groups within the NIH. In FY24, we collaborated in more than 65 different projects from 40 different investigators, with over 4000 sample runs. Among these are projects to characterize the post…
Patrick Duffy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $800,611 — In FY2024, we reported human and animal studies to investigate malaria immunology and pathogenesis, and malaria vaccine development. Highlighted in this year’s summary are results from our publications. Miotto O et al. Identification of complex Plasmodium falciparum genetic backgrounds circulating…
James M Dubois · WASHINGTON UNIVERSITY · 2024 · $458,341 — Religion is a primary driver of concerns with genomics and genomic healthcare (GGH). It is vital for research on the ethical, legal, and social implications (ELSI) of genomics to understand the role of religion in shaping public attitudes toward GGH. Ninety percent of the US public believes in some …
Vivian G Cheung · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $1 — PROJECT SUMMARY APOE4 is a major genetic risk factor for Alzheimer's Disease, which affects millions worldwide. In the United States, over 60% of Alzheimer's patients carry at least one APOE4 allele. Despite three decades of research, the absence of precision medicine targeting APOE4 remains a criti…
Shane P Crotty · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $810,280 — Project Summary Preclinical studies and early stage human trials evaluating passively transferred broadly neutralizing antibodies (bnAbs) suggest that a vaccine capable of eliciting bnAbs would provide effective protection from HIV infection. However, the difficulty of inducing bnAbs through vaccina…
Mansun Law · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $883,119 — Project Summary Hepatitis B virus (HBV) infects over 250 million people worldwide and is a leading cause of liver cirrhosis and cancer in many countries. The unique life cycle of HBV involves the generation of covalently closed circular double stranded DNA (cccDNA) in the nucleus of an infected cell…
Jacob Brenner · UNIVERSITY OF PENNSYLVANIA · 2024 · $694,692 — ABSTRACT / PROJECT SUMMARY Despite 50+ years of dissecting the pathways of acute respiratory distress syndrome (ARDS), there are still no drugs which improve its mortality. From a pharmacology perspective, this lack of clinical trial success falls into 2 major buckets: poor drug delivery to the alv…
PARHAM RAMEZANI-RAD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · 2024 · $892,826 — SUMMARY Conventional vaccine strategies have not induced successful protection to diverse HIV strains. mRNA vaccine platforms enable novel modalities of antigen delivery for innovative vaccine strategies. The use of mRNA technology for HIV vaccines holds promise to conquer major barriers to induce p…
Connie Wu · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $371,606 — PROJECT SUMMARY: RNA therapeutics are experiencing a renaissance with the clinical successes of the COVID-19 messenger RNA (mRNA) vaccines. In parallel, nanomaterials have emerged as highly promising vehicles for RNA delivery. However, despite considerable scientific advances in nanoparticle therape…
Susan L Swain · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2024 · $586,250 — ABSTRACT: How Distinct Age-Associated B Cell Subsets Can Protect the Aged from Influenza. With age, the generation of T follicular helpers from naive CD4 T cells, and of germinal center B cells from follicular B cells, both of which are essential for the generation of high affinity antibody (Ab), be…
Michael J Mitchell · UNIVERSITY OF PENNSYLVANIA · 2024 · $349,375 — PROJECT SUMMARY Pre-eclampsia is an obstetric condition that affects 5–8% of all pregnancies and is a leading cause of maternal mortality worldwide. Pre-eclampsia is characterized by the onset of maternal hypertension after 20 weeks of gestation, stemming from insufficient remodeling of the uterine …
Rachel Adria Katzenellenbogen · INDIANA UNIVERSITY INDIANAPOLIS · 2024 · $68,162 — PROJECT SUMMARY/ABSTRACT High-risk human papillomaviruses (HR HPVs) cause 5% of all cancers. There are preventive vaccines against HPV, but less than 2% of the world's target population has received them. This leaves millions of women and men at risk for HPV-associated cervical, anogenital, and hea…
Clayton C Caswell · VIRGINIA POLYTECHNIC INST AND ST UNIV · 2024 · $195,342 — Project Summary Brucella spp. are bacteria that naturally infect a variety of domesticated and wild animals leading to abortions and sterility, and these bacteria are also capable of causing debilitating human infections, which often result from human exposure to infected animals and animal product…
CARL H. JUNE · UNIVERSITY OF PENNSYLVANIA · 2024 · $3,119,164 — OVERALL PROJECT SUMMARY / ABSTRACT The long-term goals of this renewal P01 are to develop next generation immunotherapy with chimeric antigen receptor (CAR) T cells and to translate this research into new therapies with curative potential for patients with blood cancer. The CAR developed at our cent…
Michael Farkas · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2024 · $346,500 — ABSTRACT Gene therapy to treat inherited retinal dystrophies (IRDs) is finally a clinical reality. Adeno-associated virus (AAV) has led the way as a medium to transport a corrective gene to various affected retinal cell types, as well as for CRISPR/Cas9-mediated genome editing. As a long-term soluti…
Brandi Johnson-Weaver · DUKE UNIVERSITY · 2024 · $200,490 — Project Summary/Abstract: Oral immunotherapy with PALFORZIA® is a recently FDA-approved therapy to treat peanut allergy. This therapy requires daily doses of characterized peanut proteins administered orally to peanut hypersensitive individuals. A major limitation of the PALFORZIA® therapy is the po…
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $1,306,400 — We previously performed codon-pair deoptimization (CPD) of various open reading frames (ORFs) of RSV. This is done by rearranging codons of RSV open reading frames using computer algorithms and de novo gene synthesis to increase the content of normally underrepresented codon-pairs without changing a…